Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure

International Journal of Molecular Sciences

Volumn 16, Issue 2, 2015, Pages 4226-4249

  Salles, Thiago A ^a   dos Santos, Leonardo ^b   Barauna, Valério G ^b   Girardi, Adriana C C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

Author keywords

Brain natriuretic peptide; Cardiac dysfunction; Cardioprotection; Glucagon like peptide 1; Natriuresis; Renal function; Renoprotection; Stromal cell derived factor 1

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE; DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; LINAGLIPTIN; MICRORNA 29; SAXAGLIPTIN; SITAGLIPTIN; STROMAL CELL DERIVED FACTOR 1ALPHA; SUBSTANCE P; VASOACTIVE INTESTINAL POLYPEPTIDE; VILDAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; STROMAL CELL DERIVED FACTOR 1;

ANGIOGENESIS; BLOOD GLUCOSE MONITORING; CELL MIGRATION; CELL PROLIFERATION; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FOOD INTAKE; GENE DELETION; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; LUNG CONGESTION; NONHUMAN; PHASE 4 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; CHEMISTRY; METABOLISM; PATHOPHYSIOLOGY;

ANIMALIA;

ANIMALS; CHEMOKINE CXCL12; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN;

EID: 84923098839     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16024226     Document Type: Review

References (151)

1. Mill, J.G.; Stefanon, I.; dos Santos, L.; Baldo, M.P. Remodeling in the ischemic heart: The stepwise progression for heart failure. Braz. J. Med. Biol. Res. 2011, 44, 890-898.
2. Francis, G.S. Pathophysiology of chronic heart failure. Am. J. Med. 2001, 110, 37S-46S.
3. MacIver, D.H.; Dayer, M.J.; Harrison, A.J. A general theory of acute and chronic heart failure. Int. J. Cardiol. 2013, 165, 25-34.
4. Yancy, C.W.; Jessup, M.; Bozkurt, B.; Butler, J.; Casey, D.E., Jr.; Drazner, M.H.; Fonarow, G.C.; Geraci, S.A.; Horwich, T.; Januzzi, J.L.; et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the american college of cardiology foundation/american heart association task force on practice guidelines. J. Am. Coll. Cardiol. 2013, 62, e147-239.
5. Hong, W.J.; Petell, J.K.; Swank, D.; Sanford, J.; Hixson, D.C.; Doyle, D. Expression of dipeptidyl peptidase IV in rat tissues is mainly regulated at the mRNA levels. Exp. Cell Res. 1989, 182, 256-266.
6. Kenny, A.J.; Booth, A.G.; George, S.G.; Ingram, J.; Kershaw, D.; Wood, E.J.; Young, A.R. Dipeptidyl peptidase IV, a kidney brush-border serine peptidase. Biochem. J. 1976, 157, 169-182.
7. Lambeir, A.M.; Durinx, C.; Scharpe, S.; de Meester, I. Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 2003, 40, 209-294.
8. Matheeussen, V.; Baerts, L.; de Meyer, G.; de Keulenaer, G.; van der Veken, P.; Augustyns, K.; Dubois, V.; Scharpe, S.; de Meester, I. Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol. Chem. 2011, 392, 189-198.
9. Steeg, C.; Hartwig, U.; Fleischer, B. Unchanged signaling capacity of mutant CD26/dipeptidylpeptidase IV molecules devoid of enzymatic activity. Cell. Immunol. 1995, 164, 311-315.
10. Tanaka, T.; Duke-Cohan, J.S.; Kameoka, J.; Yaron, A.; Lee, I.; Schlossman, S.F.; Morimoto, C. Enhancement of antigen-induced T-cell proliferation by soluble cd26/dipeptidyl peptidase IV. Proc. Natl. Acad. Sci. USA 1994, 91, 3082-3086.
11. Ohnuma, K.; Takahashi, N.; Yamochi, T.; Hosono, O.; Dang, N.H.; Morimoto, C. Role of CD26/dipeptidyl peptidase IV in human T cell activation and function. Front. Biosci. 2008, 13, 2299-2310.
12. Yan, S.; Marguet, D.; Dobers, J.; Reutter, W.; Fan, H. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Eur. J. Immunol. 2003, 33, 1519-1527.
13. Durinx, C.; Lambeir, A.M.; Bosmans, E.; Falmagne, J.B.; Berghmans, R.; Haemers, A.; Scharpe, S.; de Meester, I. Molecular characterization of dipeptidyl peptidase activity in serum: Soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-pro dipeptides. Eur. J. Biochem. 2000, 267, 5608-5613.
14. Cordero, O.J.; Salgado, F.J.; Nogueira, M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol. Immunother. 2009, 58, 1723-1747.
15. Varga, T.; Somogyi, A.; Barna, G.; Wichmann, B.; Nagy, G.; Racz, K.; Selmeci, L.; Firneisz, G. Higher serum DPP-4 enzyme activity and decreased lymphocyte CD26 expression in type 1 diabetes. Pathol. Oncol. Res. 2011, 17, 925-930.
16. Eric-Nikolic, A.; Matic, I.Z.; Dordevic, M.; Milovanovic, Z.; Markovic, I.; Dzodic, R.; Inic, M.; Srdic-Rajic, T.; Jevric, M.; Gavrilovic, D.; et al. Serum DPPIV activity and CD26 expression on lymphocytes in patients with benign or malignant breast tumors. Immunobiology 2011, 216, 942-946.
17. Lamers, D.; Famulla, S.; Wronkowitz, N.; Hartwig, S.; Lehr, S.; Ouwens, D.M.; Eckardt, K.; Kaufman, J.M.; Ryden, M.; Muller, S.; et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011, 60, 1917-1925.
18. Sell, H.; Bluher, M.; Kloting, N.; Schlich, R.; Willems, M.; Ruppe, F.; Knoefel, W.T.; Dietrich, A.; Fielding, B.A.; Arner, P.; et al. Adipose dipeptidyl peptidase-4 and obesity: Correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care 2013, 36, 4083-4090.
19. Rohrborn, D.; Eckel, J.; Sell, H. Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells. FEBS Lett. 2014, 588, 3870-3877.
20. Hopsu-Havu, V.K.; Sarimo, S.R. Purification and characterization of an aminopeptidase hydrolyzing glycyl-proline-naphthylamide. Hoppe Seylers Z. Physiol. Chem. 1967, 348, 1540-1550.
21. Marguet, D.; Baggio, L.; Kobayashi, T.; Bernard, A.M.; Pierres, M.; Nielsen, P.F.; Ribel, U.; Watanabe, T.; Drucker, D.J.; Wagtmann, N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. USA 2000, 97, 6874-6879.
22. Gutniak, M.; Orskov, C.; Holst, J.J.; Ahren, B.; Efendic, S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 1992, 326, 1316-1322.
23. Girardi, A.C.; Degray, B.C.; Nagy, T.; Biemesderfer, D.; Aronson, P.S. Association of Na+-H+ exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule. J. Biol. Chem. 2001, 276, 46671-46677.
24. Schultheis, P.J.; Clarke, L.L.; Meneton, P.; Miller, M.L.; Soleimani, M.; Gawenis, L.R.; Riddle, T.M.; Duffy, J.J.; Doetschman, T.; Wang, T.; et al. Renal and intestinal absorptive defects in mice lacking the NHE3 Na+/H+ exchanger. Nat. Genet. 1998, 19, 282-285.
25. Girardi, A.C.; Knauf, F.; Demuth, H.U.; Aronson, P.S. Role of dipeptidyl peptidase IV in regulating activity of Na+/H+ exchanger isoform nhe3 in proximal tubule cells. Am. J. Physiol. Cell Physiol. 2004, 287, C1238-C1245.
26. Girardi, A.C.; Fukuda, L.E.; Rossoni, L.V.; Malnic, G.; Reboucas, N.A. Dipeptidyl peptidase IV inhibition downregulates Na+-H+ exchanger NHE3 in rat renal proximal tubule. Am. J. Physiol. Ren. Physiol. 2008, 294, F414-F422.
27. Bauvois, B. A collagen-binding glycoprotein on the surface of mouse fibroblasts is identified as dipeptidyl peptidase IV. Biochem. J. 1988, 252, 723-731.
28. Loster, K.; Zeilinger, K.; Schuppan, D.; Reutter, W. The cysteine-rich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site. Biochem. Biophys. Res. Commun. 1995, 217, 341-348.
29. Piazza, G.A.; Callanan, H.M.; Mowery, J.; Hixson, D.C. Evidence for a role of dipeptidyl peptidase IV in fibronectin-mediated interactions of hepatocytes with extracellular matrix. Biochem. J. 1989, 262, 327-334.
30. Cheng, H.C.; Abdel-Ghany, M.; Elble, R.C.; Pauli, B.U. Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin. J. Biol. Chem. 1998, 273, 24207-24215.
31. Ghersi, G.; Dong, H.; Goldstein, L.A.; Yeh, Y.; Hakkinen, L.; Larjava, H.S.; Chen, W.T. Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J. Biol. Chem. 2002, 277, 29231-29241.
32. Takahashi, A.; Asakura, M.; Ito, S.; Min, K.D.; Shindo, K.; Yan, Y.; Liao, Y.; Yamazaki, S.; Sanada, S.; Asano, Y.; et al. Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice. Am. J. Physiol. Heart Circ. Physiol. 2013, 304, H1361-H1369.
33. Dos Santos, L.; Salles, T.A.; Arruda-Junior, D.F.; Campos, L.C.; Pereira, A.C.; Barreto, A.L.; Antonio, E.L.; Mansur, A.J.; Tucci, P.J.; Krieger, J.E.; et al. Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure. Circ. Heart Fail. 2013, 6, 1029-1038.
34. Shigeta, T.; Aoyama, M.; Bando, Y.K.; Monji, A.; Mitsui, T.; Takatsu, M.; Cheng, X.W.; Okumura, T.; Hirashiki, A.; Nagata, K.; et al. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and-independent actions. Circulation 2012, 126, 1838-1851.
35. Chaykovska, L.; von Websky, K.; Rahnenfuhrer, J.; Alter, M.; Heiden, S.; Fuchs, H.; Runge, F.; Klein, T.; Hocher, B. Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS One 2011, 6, e27861.
36. Bostick, B.; Habibi, J.; Ma, L.; Aroor, A.; Rehmer, N.; Hayden, M.R.; Sowers, J.R. Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of western diet induced obesity. Metabolism 2014, 63, 1000-1011.
37. Connelly, K.A.; Bowskill, B.B.; Advani, S.L.; Thai, K.; Chen, L.H.; Kabir, M.G.; Gilbert, R.E.; Advani, A. Dipeptidyl peptidase-4 inhibition improves left ventricular function in chronic kidney disease. Clin. Investig Med. 2014, 37, 172-185.
38. Miyoshi, T.; Nakamura, K.; Yoshida, M.; Miura, D.; Oe, H.; Akagi, S.; Sugiyama, H.; Akazawa, K.; Yonezawa, T.; Wada, J.; et al. Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic β-adrenergic stimulation in rats. Cardiovasc. Diabetol. 2014, 13, doi:10.1186/1475-2840-13-43.
39. Pacheco, B.P.; Crajoinas, R.O.; Couto, G.K.; Davel, A.P.; Lessa, L.M.; Rossoni, L.V.; Girardi, A.C. Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J. Hypertens. 2011, 29, 520-528.
40. Girardi, A.C.; di Sole, F. Deciphering the mechanisms of the Na+/H+ exchanger-3 regulation in organ dysfunction. Am. J. Physiol. Cell Physiol. 2012, 302, C1569-C1587.
41. Zheng, T.; Baskota, A.; Gao, Y.; Tian, H.; Yang, F. Increased plasma dipeptidyl peptidase 4 activities predict new-onset microalbuminuria in association with its proinflammatory effects in chinese without diabetes: A four-year prospective study. Nephrol. Dial. Transplant. 2014, doi:10.1093/ndt/gfu312
42. Agrawal, N.K.; Kant, S. Targeting inflammation in diabetes: Newer therapeutic options. World J. Diabetes 2014, 5, 697-710.
43. Tremblay, A.J.; Lamarche, B.; Deacon, C.F.; Weisnagel, S.J.; Couture, P. Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes. Metabolism 2014, 63, 1141-1148.
44. Lourenco, P.; Frioes, F.; Silva, N.; Guimaraes, J.T.; Bettencourt, P. Dipeptidyl peptidase IV and mortality after an acute heart failure episode. J. Cardiovasc. Pharmacol. 2013, 62, 138-142.
45. Gomez, N.; Matheeussen, V.; Damoiseaux, C.; Tamborini, A.; Merveille, A.C.; Jespers, P.; Michaux, C.; Clercx, C.; de Meester, I.; Mc Entee, K. Effect of heart failure on dipeptidyl peptidase IV activity in plasma of dogs. J. Vet. Intern. Med. 2012, 26, 929-934.
46. Kanasaki, K.; Shi, S.; Kanasaki, M.; He, J.; Nagai, T.; Nakamura, Y.; Ishigaki, Y.; Kitada, M.; Srivastava, S.P.; Koya, D. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes 2014, 63, 2120-2131.
47. Melo, S.F.; Fernandes, T.; Barauna, V.G.; Matos, K.C.; Santos, A.A.; Tucci, P.J.; Oliveira, E.M. Expression of microRNA-29 and collagen in cardiac muscle after swimming training in myocardial-infarcted rats. Cell. Physiol. Biochem. 2014, 33, 657-669.
48. Van Rooij, E.; Sutherland, L.B.; Thatcher, J.E.; DiMaio, J.M.; Naseem, R.H.; Marshall, W.S.; Hill, J.A.; Olson, E.N. Dysregulation of microRNAs after myocardial infarction reveals a role of mir-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. USA 2008, 105, 13027-13032.
49. Czuriga, D.; Paulus, W.J.; Czuriga, I.; Edes, I.; Papp, Z.; Borbely, A. Cellular mechanisms for diastolic dysfunction in the human heart. Curr. Pharm. Biotechnol. 2012, 13, 2532-2538.
50. Ramasamy, R.; Schmidt, A.M. Receptor for advanced glycation end products (rage) and implications for the pathophysiology of heart failure. Curr. Heart Fail. Rep. 2012, 9, 107-116.
51. Cordero, O.J.; Salgado, F.J.; Vinuela, J.E.; Nogueira, M. Interleukin-12 enhances CD26 expression and dipeptidyl peptidase IV function on human activated lymphocytes. Immunobiology 1997, 197, 522-533.
52. Stefanovic, V.; Ardaillou, N.; Vlahovic, P.; Placier, S.; Ronco, P.; Ardaillou, R. Interferon-γ induces dipeptidylpeptidase IV expression in human glomerular epithelial cells. Immunology 1993, 80, 465-470.
53. Riemann, D.; Kehlen, A.; Langner, J. Stimulation of the expression and the enzyme activity of aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 on human renal cell carcinoma cells and renal tubular epithelial cells by T cell-derived cytokines, such as IL-4 and IL-13. Clin. Exp. Immunol. 1995, 100, 277-283.
54. Yamabe, T.; Takakura, K.; Sugie, K.; Kitaoka, Y.; Takeda, S.; Okubo, Y.; Teshigawara, K.; Yodoi, J.; Hori, T. Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15. Immunology 1997, 91, 151-158.
55. Ishibashi, Y.; Matsui, T.; Maeda, S.; Higashimoto, Y.; Yamagishi, S. Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc. Diabetol. 2013, 12, doi:10.1186/1475-2840-12-125.
56. Tahara, N.; Yamagishi, S.; Takeuchi, M.; Tahara, A.; Kaifu, K.; Ueda, S.; Okuda, S.; Imaizumi, T. Serum levels of advanced glycation end products (ages) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans. Clin. Biochem. 2013, 46, 300-303.
57. Eltzschig, H.K.; Faigle, M.; Knapp, S.; Karhausen, J.; Ibla, J.; Rosenberger, P.; Odegard, K.C.; Laussen, P.C.; Thompson, L.F.; Colgan, S.P. Endothelial catabolism of extracellular adenosine during hypoxia: The role of surface adenosine deaminase and CD26. Blood 2006, 108, 1602-1610.
58. Matheeussen, V.; Jungraithmayr, W.; de Meester, I. Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury. Pharmacol. Ther. 2012, 136, 267-282.
59. Drucker, D.J. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat. Clin. Pract. Endocrinol. Metab. 2005, 1, 22-31.
60. Lund, A.; Knop, F.K.; Vilsboll, T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities. Eur. J. Int. Med. 2014, 25, 407-414.
61. Scheen, A.J. A review of gliptins for 2014. Expert Opin. Pharmacother. 2015, 16, 43-62.
62. Ban, K.; Noyan-Ashraf, M.H.; Hoefer, J.; Bolz, S.S.; Drucker, D.J.; Husain, M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation 2008, 117, 2340-2350.
63. Liu, Q.; Anderson, C.; Broyde, A.; Polizzi, C.; Fernandez, R.; Baron, A.; Parkes, D.G. Glucagon-like peptide-1 and the exenatide analogue AC 3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc. Diabetol. 2010, 9, 76, doi:10.1186/1475-2840-9-76.
64. Poornima, I.; Brown, S.B.; Bhashyam, S.; Parikh, P.; Bolukoglu, H.; Shannon, R.P. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circulation 2008, 1, 153-160.
65. Ravassa, S.; Zudaire, A.; Carr, R.D.; Diez, J. Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am. J. Physiol. 2011, 300, H1361-H1372.
66. Timmers, L.; Henriques, J.P.; de Kleijn, D.P.; Devries, J.H.; Kemperman, H.; Steendijk, P.; Verlaan, C.W.; Kerver, M.; Piek, J.J.; Doevendans, P.A.; et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J. Am. Coll. Cardiol. 2009, 53, 501-510.
67. Moreno, C.; Mistry, M.; Roman, R.J. Renal effects of glucagon-like peptide in rats. Eur. J. Pharmacol. 2002, 434, 163-167.
68. Crajoinas, R.O.; Oricchio, F.T.; Pessoa, T.D.; Pacheco, B.P.; Lessa, L.M.; Malnic, G.; Girardi, A.C. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am. J. Physiol. Ren. Physiol. 2011, 301, F355-F363.
69. Rieg, T.; Gerasimova, M.; Murray, F.; Masuda, T.; Tang, T.; Rose, M.; Drucker, D.J.; Vallon, V. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am. J. Physiol. Ren. Physiol. 2012, 303, F963-F971.
70. Thomson, S.C.; Kashkouli, A.; Singh, P. Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat. Am. J. Physiol. Ren. Physiol. 2013, 304, F137-F144.
71. Skov, J.; Holst, J.J.; Gotze, J.P.; Frokiaer, J.; Christiansen, J.S. Glucagon-like peptide-1: Effect on pro-atrial natriuretic peptide in healthy males. Endocr. Connect. 2014, 3, 11-16.
72. Gutzwiller, J.P.; Hruz, P.; Huber, A.R.; Hamel, C.; Zehnder, C.; Drewe, J.; Gutmann, H.; Stanga, Z.; Vogel, D.; Beglinger, C. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion 2006, 73, 142-150.
73. Gutzwiller, J.P.; Tschopp, S.; Bock, A.; Zehnder, C.E.; Huber, A.R.; Kreyenbuehl, M.; Gutmann, H.; Drewe, J.; Henzen, C.; Goeke, B.; et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J. Clin. Endocrinol. Metab. 2004, 89, 3055-3061.
74. Skov, J.; Dejgaard, A.; Frokiaer, J.; Holst, J.J.; Jonassen, T.; Rittig, S.; Christiansen, J.S. Glucagon-like peptide-1 (GLP-1): Effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J. Clin. Endocrinol. Metab. 2013, 98, E664-E671.
75. Kim, M.; Platt, M.J.; Shibasaki, T.; Quaggin, S.E.; Backx, P.H.; Seino, S.; Simpson, J.A.; Drucker, D.J. GLP-1 receptor activation and epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat. Med. 2013, 19, 567-575.
76. Katagiri, D.; Hamasaki, Y.; Doi, K.; Okamoto, K.; Negishi, K.; Nangaku, M.; Noiri, E. Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection. J. Am. Soc. Nephrol. 2013, 24, 2034-2043.
77. Panchapakesan, U.; Mather, A.; Pollock, C. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clin. Sci. 2013, 124, 17-26.
78. Tanaka, T.; Higashijima, Y.; Wada, T.; Nangaku, M. The potential for renoprotection with incretin-based drugs. Kidney Int. 2014, 86, 701-711.
79. Cavusoglu, T.; Erbas, O.; Karadeniz, T.; Akdemir, O.; Acikgoz, E.; Karadeniz, M.; Tuglu, M.I.; Ates, U. Comparison of nephron-protective effects of enalapril and GLP analogues (exenatide) in diabetic nephropathy. Exp. Clin. Endocrinol. Diabetes 2014, 122, 327-333.
80. Chen, Y.T.; Tsai, T.H.; Yang, C.C.; Sun, C.K.; Chang, L.T.; Chen, H.H.; Chang, C.L.; Sung, P.H.; Zhen, Y.Y.; Leu, S.; et al. Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. J. Transl. Med. 2013, 11, 270, doi:10.1186/1479-5876-11-270.
81. Bose, A.K.; Mocanu, M.M.; Carr, R.D.; Brand, C.L.; Yellon, D.M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54, 146-151.
82. Nikolaidis, L.A.; Mankad, S.; Sokos, G.G.; Miske, G.; Shah, A.; Elahi, D.; Shannon, R.P. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109, 962-965.
83. Noyan-Ashraf, M.H.; Momen, M.A.; Ban, K.; Sadi, A.M.; Zhou, Y.Q.; Riazi, A.M.; Baggio, L.L.; Henkelman, R.M.; Husain, M.; Drucker, D.J. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58, 975-983.
84. DeNicola, M.; Du, J.; Wang, Z.; Yano, N.; Zhang, L.; Wang, Y.; Qin, G.; Zhuang, S.; Zhao, T.C. Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium. Am. J. Physiol. Endocrinol. Metab. 2014, 307, E630-E643.
85. Lonborg, J.; Vejlstrup, N.; Kelbaek, H.; Nepper-Christensen, L.; Jorgensen, E.; Helqvist, S.; Holmvang, L.; Saunamaki, K.; Botker, H.E.; Kim, W.Y.; et al. Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with stemi and the association with exenatide treatment: Results from a randomized study. Diabetes 2014, 63, 2474-2485.
86. Avogaro, A.; Vigili de Kreutzenberg, S.; Fadini, G.P. Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy. Curr. Diabetes Rep. 2014, 14, 483, doi:10.1007/s11892-014-0483-3.
87. Picatoste, B.; Ramirez, E.; Caro-Vadillo, A.; Iborra, C.; Ares-Carrasco, S.; Egido, J.; Tunon, J.; Lorenzo, O. Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. PLoS One 2013, 8, e78330.
88. Nystrom, T.; Gonon, A.T.; Sjoholm, A.; Pernow, J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul. Pept. 2005, 125, 173-177.
89. Nystrom, T.; Gutniak, M.K.; Zhang, Q.; Zhang, F.; Holst, J.J.; Ahren, B.; Sjoholm, A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab. 2004, 287, E1209-E1215.
90. Crajoinas, R.O.; Savignano, F.A.; Nakamuta, J.; Girardi, A.C. Renal vascular relaxation response to glucagon-like peptide-1 (GLP-1) is impaired in spontaneously hypertensive rats (SHR). FASEB J. 2012, 26, (1_MeetingAbstracts): 688.2.
91. Limei, L.; Jian, L.; Yu, H. Protective effects of glucagon-like peptide-1 on endothelial function in hypertension. J. Cardiovasc. Pharmacol. 2014, doi:10.1097/FJC.0000000000000176.
92. Shimizu, H.; Masuta, K.; Aono, K.; Asada, H.; Sasakura, K.; Tamaki, M.; Sugita, K.; Yamada, K. Molecular forms of human brain natriuretic peptide in plasma. Clin. Chim. Acta 2002, 316, 129-135.
93. Volpe, M.; Rubattu, S.; Burnett, J. Natriuretic peptides in cardiovascular diseases: Current use and perspectives. Eur. Heart J. 2013, 35, 419-425.
94. McGregor, A.; Richards, M.; Espiner, E.; Yandle, T.; Ikram, H. Brain natriuretic peptide administered to man: Actions and metabolism. J. Clin. Endocrinol. Metab. 1990, 70, 1103-1107.
95. Gunning, M.; Ballermann, B.J.; Silva, P.; Brenner, B.M.; Zeidel, M.L. Brain natriuretic peptide: Interaction with renal anp system. Am. J. Physiol. 1990, 258, F467-F472.
96. Morita, H.; Nishida, Y.; Motochigawa, H.; Kangawa, K.; Minamino, N.; Matsuo, H.; Hosomi, H. Effects of brain natriuretic peptide on renal nerve activity in conscious rabbits. Am. J. Physiol. 1989, 256, R792-R796.
97. Remes, J. Neuroendocrine activation after myocardial infarction. Br. Heart J. 1994, 72, S65-S69.
98. Riegger, G.A.; Kromer, E.P.; Kochsiek, K. Human atrial natriuretic peptide: Plasma levels, hemodynamic, hormonal, and renal effects in patients with severe congestive heart failure. J. Cardiovasc. Pharmacol. 1986, 8, 1107-1112.
99. Cody, R.J.; Atlas, S.A.; Laragh, J.H.; Kubo, S.H.; Covit, A.B.; Ryman, K.S.; Shaknovich, A.; Pondolfino, K.; Clark, M.; Camargo, M.J.; et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J. Clin. Investig. 1986, 78, 1362-1374.
100. Morita, E.; Yasue, H.; Yoshimura, M.; Ogawa, H.; Jougasaki, M.; Matsumura, T.; Mukoyama, M.; Nakao, K. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993, 88, 82-91.
101. Ledwidge, M.; Gallagher, J.; Conlon, C.; Tallon, E.; O'Connell, E.; Dawkins, I.; Watson, C.; O'Hanlon, R.; Bermingham, M.; Patle, A.; et al. Natriuretic peptide-based screening and collaborative care for heart failure: The stop-HF randomized trial. JAMA 2013, 310, 66-74.
102. Jensen, K.T.; Eiskjaer, H.; Carstens, J.; Pedersen, E.B. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin. Sci. 1999, 96, 5-15.
103. Charloux, A.; Piquard, F.; Doutreleau, S.; Brandenberger, G.; Geny, B. Mechanisms of renal hyporesponsiveness to ANP in heart failure. Eur. J. Clin. Investig. 2003, 33, 769-778.
104. Cadnapaphornchai, M.A.; Gurevich, A.K.; Weinberger, H.D.; Schrier, R.W. Pathophysiology of sodium and water retention in heart failure. Cardiology 2001, 96, 122-131.
105. Inoue, B.H.; dos Santos, L.; Pessoa, T.D.; Antonio, E.L.; Pacheco, B.P.; Savignano, F.A.; Carraro-Lacroix, L.R.; Tucci, P.J.; Malnic, G.; Girardi, A.C. Increased NHE3 abundance and transport activity in renal proximal tubule of rats with heart failure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012, 302, R166-R174
106. Hawkridge, A.M.; Heublein, D.M.; Bergen, H.R.; Cataliotti, A.; Burnett, J.C.; Muddiman, D.C. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc. Natl. Acad. Sci. USA 2005, 102, 17442-17447.
107. Miller, W.L.; Phelps, M.A.; Wood, C.M.; Schellenberger, U.; van Le, A.; Perichon, R.; Jaffe, A.S. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of b-type natriuretic peptide in patients with chronic heart failure. Circ. Heart Fail. 2011, 4, 355-360.
108. Brandt, I.; Lambeir, A.M.; Ketelslegers, J.M.; Vanderheyden, M.; Scharpe, S.; de Meester, I. Dipeptidyl-peptidase IV converts intact b-type natriuretic peptide into its des-serpro form. Clin. Chem. 2006, 52, 82-87.
109. Boerrigter, G.; Costello-Boerrigter, L.C.; Harty, G.J.; Lapp, H.; Burnett, J.C., Jr. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 292, R897-R901.
110. Gomez, N.; Touihri, K.; Matheeussen, V.; Mendes Da Costa, A.; Mahmoudabady, M.; Mathieu, M.; Baerts, L.; Peace, A.; Lybaert, P.; Scharpe, S.; et al. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur. J. Heart Fail. 2012, 14, 14-21.
111. Doring, Y.; Pawig, L.; Weber, C.; Noels, H. The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease. Front. Physiol. 2014, 5, 212, doi:10.3389/fphys.2014.00212.
112. Takahashi, M. Role of the SDF-1/CXCR4 system in myocardial infarction. Circ. J. 2010, 74, 418-423.
113. Kanki, S.; Segers, V.F.; Wu, W.; Kakkar, R.; Gannon, J.; Sys, S.U.; Sandrasagra, A.; Lee, R.T. Stromal cell-derived factor-1 retention and cardioprotection for ischemic myocardium. Circ. Heart Fail. 2011, 4, 509-518.
114. Salvucci, O.; Yao, L.; Villalba, S.; Sajewicz, A.; Pittaluga, S.; Tosato, G. Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood 2002, 99, 2703-2711.
115. Segers, V.F.; Revin, V.; Wu, W.; Qiu, H.; Yan, Z.; Lee, R.T.; Sandrasagra, A. Protease-resistant stromal cell-derived factor-1 for the treatment of experimental peripheral artery disease. Circulation 2011, 123, 1306-1315.
116. Segers, V.F.; Tokunou, T.; Higgins, L.J.; MacGillivray, C.; Gannon, J.; Lee, R.T. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation 2007, 116, 1683-1692.
117. Zaruba, M.M.; Theiss, H.D.; Vallaster, M.; Mehl, U.; Brunner, S.; David, R.; Fischer, R.; Krieg, L.; Hirsch, E.; Huber, B.; et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 2009, 4, 313-323. 118.
118. Theiss, H.D.; Vallaster, M.; Rischpler, C.; Krieg, L.; Zaruba, M.M.; Brunner, S.; Vanchev, Y.; Fischer, R.; Grobner, M.; Huber, B.; et al. Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis. Stem Cell Res. 2011, 7, 244-255.
119. Fortunato, O.; Spinetti, G.; Specchia, C.; Cangiano, E.; Valgimigli, M.; Madeddu, P. Migratory activity of circulating progenitor cells and serum SDF-1α predict adverse events in patients with myocardial infarction. Cardiovasc. Res. 2013, 100, 192-200.
120. Subramanian, S.; Liu, C.; Aviv, A.; Ho, J.E.; Courchesne, P.; Muntendam, P.; Larson, M.G.; Cheng, S.; Wang, T.J.; Mehta, N.N.; et al. Stromal cell-derived factor 1 as a biomarker of heart failure and mortality risk. Arterioscler. Thromb. Vasc. Biol. 2014, 34, 2100-2105.
121. Fadini, G.P.; Boscaro, E.; Albiero, M.; Menegazzo, L.; Frison, V.; de Kreutzenberg, S.; Agostini, C.; Tiengo, A.; Avogaro, A. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: Possible role of stromal-derived factor-1α. Diabetes Care 2010, 33, 1607-1609.
122. Henning, R.J.; Sawmiller, D.R. Vasoactive intestinal peptide: Cardiovascular effects. Cardiovasc. Res. 2001, 49, 27-37.
123. Dvorakova, M.C. Cardioprotective role of the VIP signaling system. Drug News Perspect 2005, 18, 387-391.
124. Vacas, E.; Bajo, A.M.; Schally, A.V.; Sanchez-Chapado, M.; Prieto, J.C.; Carmena, M.J. Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinoma. Mol. Cell. Endocrinol. 2012, 365, 212-222.
125. Rosa, R.M.; Silva, P.; Stoff, J.S.; Epstein, F.H. Effect of vasoactive intestinal peptide on isolated perfused rat kidney. Am. J. Physiol. 1985, 249, E494-E497.
126. Lambeir, A.M.; Durinx, C.; Proost, P.; van Damme, J.; Scharpe, S.; de Meester, I. Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. FEBS Lett. 2001, 507, 327-330.
127. Dehlin, H.M.; Levick, S.P. Substance P in heart failure: The good and the bad. Int. J. Cardiol. 2014, 170, 270-277.
128. Tousoulis, D.; Tentolouris, C.; Crake, T.; Katsimaglis, G.; Stefanadis, C.; Toutouzas, P.; Davies, G.J. Effects of l-and d-arginine on the basal tone of human diseased coronary arteries and their responses to substance P. Heart 1999, 81, 505-511.
129. Ren, J.Y.; Song, J.X.; Lu, M.Y.; Chen, H. Cardioprotection by ischemic postconditioning is lost in isolated perfused heart from diabetic rats: Involvement of transient receptor potential vanilloid 1, calcitonin gene-related peptide and substance P. Regul. Pept. 2011, 169, 49-57.
130. Chiao, H.; Caldwell, R.W. The role of substance P in myocardial dysfunction during ischemia and reperfusion. Naunyn Schmiedebergs Arch. Pharmacol. 1996, 353, 400-407.
131. Mentlein, R.; Dahms, P.; Grandt, D.; Kruger, R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul. Pept. 1993, 49, 133-144.
132. Silva, A.P.; Cavadas, C.; Grouzmann, E. Neuropeptide y and its receptors as potential therapeutic drug targets. Clin. Chim. Acta 2002, 326, 3-25.
133. Zukowska, Z.; Grant, D.S.; Lee, E.W. Neuropeptide y: A novel mechanism for ischemic angiogenesis. Trends Cardiovasc. Med. 2003, 13, 86-92.
134. Movafagh, S.; Hobson, J.P.; Spiegel, S.; Kleinman, H.K.; Zukowska, Z. Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors. FASEB J. 2006, 20, 1924-1926.
135. Maisel, A.S.; Scott, N.A.; Motulsky, H.J.; Michel, M.C.; Boublik, J.H.; Rivier, J.E.; Ziegler, M.; Allen, R.S.; Brown, M.R. Elevation of plasma neuropeptide Y levels in congestive heart failure. Am. J. Med. 1989, 86, 43-48.
136. Hulting, J.; Sollevi, A.; Ullman, B.; Franco-Cereceda, A.; Lundberg, J.M. Plasma neuropeptide Y on admission to a coronary care unit: Raised levels in patients with left heart failure. Cardiovasc. Res. 1990, 24, 102-108.
137. Nichols, G.A.; Gullion, C.M.; Koro, C.E.; Ephross, S.A.; Brown, J.B. The incidence of congestive heart failure in type 2 diabetes: An update. Diabetes Care 2004, 27, 1879-1884.
138. Sauve, M.; Ban, K.; Momen, M.A.; Zhou, Y.Q.; Henkelman, R.M.; Husain, M.; Drucker, D.J. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010, 59, 1063-1073.
139. Yin, M.; Sillje, H.H.; Meissner, M.; van Gilst, W.H.; de Boer, R.A. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc. Diabetol. 2011, 10, doi:10.1186/1475-2840-10-85.
140. Arruda-Junior, D.F.; Socas, L.J.; Dariolli, R.; Antonio, E.L.; Tucci, P.J.; dos Santos, L.; Girardi, A.C. In Dipeptidyl Peptidase IV Inhibition Ameliorates Cardiorenal Function in Experimental Heart Failure; Experimental Biology: San Diego, CA, USA, 2014.
141. Read, P.A.; Khan, F.Z.; Heck, P.M.; Hoole, S.P.; Dutka, D.P. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ. Cardiovasc. Imaging 2010, 3, 195-201.
142. Witteles, R.M.; Keu, K.V.; Quon, A.; Tavana, H.; Fowler, M.B. Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy. J. Card. Fail. 2012, 18, 804-809.
143. Giannocco, G.; Oliveira, K.C.; Crajoinas, R.O.; Venturini, G.; Salles, T.A.; Fonseca-Alaniz, M.H.; Maciel, R.M.; Girardi, A.C. Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats. Eur. J. Pharmacol. 2013, 698, 74-86.
144. Scirica, B.M.; Bhatt, D.L.; Braunwald, E.; Steg, P.G.; Davidson, J.; Hirshberg, B.; Ohman, P.; Frederich, R.; Wiviott, S.D.; Hoffman, E.B.; et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 2013, 369, 1317-1326.
145. White, W.B.; Cannon, C.P.; Heller, S.R.; Nissen, S.E.; Bergenstal, R.M.; Bakris, G.L.; Perez, A.T.; Fleck, P.R.; Mehta, C.R.; Kupfer, S.; et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 2013, 369, 1327-1335.
146. Scirica, B.M.; Braunwald, E.; Raz, I.; Cavender, M.A.; Morrow, D.A.; Jarolim, P.; Udell, J.A.; Mosenzon, O.; Im, K.; Umez-Eronini, A.A.; et al. Heart failure, saxagliptin, and diabetes mellitus: Observations from the savor-timi 53 randomized trial. Circulation 2014, 130, 1579-1588.
147. White, W.B.; Zannad, F. Saxagliptin, alogliptin, and cardiovascular outcomes. N. Engl. J. Med. 2014, 370, 483-484.
148. McMurray, J.J.V. Vildagliptin Shows no Adverse Effect on Ejection Fraction in Diabetic Patients with HF. In Proceedings of the Heart Failure Congress 2013, Lisbon, Portugal, 25-28 May 2013.
149. Krum, H.; Lukashevich, V.; Bolli, G.B.; Kozlovski, P.; Kothny, W.; Ponikowski, P. No Significant Difference in Risk of Heart Failure Hospitalization with Vildagliptin in Diabetic Patients with Systolic Chronic Heart Failure: Vividd Study; American Diabetes Association, 74th Scientific Sessions: San Francisco, CA, USA, 2014.
150. ClinicalTrials.gov. CAROLINA: Cardiovascular Outcome Study of Linagliptin vs. Glimepiride in Patients With Type 2 Diabetes. Available online: https://clinicaltrials.gov/ct2/show/ NCT01243424 (accessed on 4 February 2015).
151. ClinicalTrials.gov. Sitagliptin Cardiovascular Outcome Study (MK-0431-082) (TECOS). Available online: https://clinicaltrials.gov/ct2/show/NCT00790205 (accessed on 28 January 2015).